Hawkeye Announces Letter of Intent to Acquire Six15 Technologies

Rich Ryan, CEO of Six15, commented, "We view the anticipated Agreement and subsequent capital raise as the final element needed to catalyze the hyper-growth phase of our business plan. We further believe our evolving narrative will be well-suited to attract and build long-term investor interest as a public company."

Hawkeye Systems, Inc. (OTCQB:HWKE) (“Hawkeye”), a technology holding company, is pleased to announce today it has signed a Letter of Intent (LOI) to acquire Six15 Technologies (“Six15”), a technology company that designs, develops, and manufactures head-up displays (HUDs) for enterprise and defense users.

Hawkeye is currently expediting the completion of due diligence to finalize a definitive Agreement (“Agreement”) to complete an all-stock purchase of 100% of the shares of Six15. The Agreement will effectuate a reverse reorganization of the two companies in conjunction with an proposed growth capital financing.

Corby Marshall, CEO of Hawkeye, stated, “We are pleased to reach the successful culmination of our M&A process with the announcement of a truly robust growth acquisition opportunity in Six15.

Combining world-class technology with accomplished industry leadership, the Six15 Agreement is expected to return the Company to its original tech mission and its focus on building sustainable long- term shareholder value.”

Rich Ryan, CEO of Six15, commented, “We view the anticipated Agreement and subsequent capital raise as the final element needed to catalyze the hyper-growth phase of our business plan. We further believe our evolving narrative will be well-suited to attract and build long-term investor interest as a public company.”

Hawkeye anticipates there will be a name and symbol change as part of the transaction. A reverse stock split is also being discussed.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.